In the past week, LCID stock has gone down by -2.84%, with a monthly decline of -11.34% and a quarterly plunge of -11.81%. The volatility ratio for the week is 3.58%, and the volatility levels for the last 30 days are 4.57% for Lucid Group Inc The simple moving average for the last 20 days is -2.87% for LCID stock, with a simple moving average of 6.63% for the last 200 days.
Is It Worth Investing in Lucid Group Inc (NASDAQ: LCID) Right Now?
Moreover, the 36-month beta value for LCID is 1.05. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 12 as “hold,” and 3 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LCID is 871.17M and currently, short sellers hold a 28.21% of that float. On October 15, 2024, LCID’s average trading volume was 34.39M shares.
LCID) stock’s latest price update
Lucid Group Inc (NASDAQ: LCID) has seen a rise in its stock price by 0.37 in relation to its previous close of 3.33. However, the company has experienced a -2.84% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-10-15 that Patent covers proprietary method using methylation of the CCNA1 gene to help detect esophageal precancer and cancer NEW YORK, Oct. 15, 2024 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its proprietary method of using methylation of the cyclin-A1 (CCNA1) gene to help detect esophageal precancer and cancer, a key component of its EsoGuard® Esophageal DNA Test. “This patent strengthens the already robust intellectual property portfolio underlying our groundbreaking technologies and will provide strong protection for the CCNA1 methylation assay method which is at the heart of the EsoGuard assay,” said Lishan Aklog, M.D.
Analysts’ Opinion of LCID
Many brokerage firms have already submitted their reports for LCID stocks, with Cantor Fitzgerald repeating the rating for LCID by listing it as a “Neutral.” The predicted price for LCID in the upcoming period, according to Cantor Fitzgerald is $4 based on the research report published on August 06, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see LCID reach a price target of $2.90. The rating they have provided for LCID stocks is “Neutral” according to the report published on April 22nd, 2024.
Cantor Fitzgerald gave a rating of “Underweight” to LCID, setting the target price at $4 in the report published on February 22nd of the current year.
LCID Trading at -5.17% from the 50-Day Moving Average
After a stumble in the market that brought LCID to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.88% of loss for the given period.
Volatility was left at 4.57%, however, over the last 30 days, the volatility rate increased by 3.58%, as shares sank -12.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.67% upper at present.
During the last 5 trading sessions, LCID fell by -3.49%, which changed the moving average for the period of 200-days by -22.07% in comparison to the 20-day moving average, which settled at $3.44. In addition, Lucid Group Inc saw -20.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LCID starting from Bach Eric, who sale 89,959 shares at the price of $3.14 back on Aug 16 ’24. After this action, Bach Eric now owns 2,028,268 shares of Lucid Group Inc, valued at $282,471 using the latest closing price.
ERIC M BACH, the Officer of Lucid Group Inc, proposed sale 89,959 shares at $3.14 during a trade that took place back on Aug 16 ’24, which means that ERIC M BACH is holding shares at $282,489 based on the most recent closing price.
Stock Fundamentals for LCID
Current profitability levels for the company are sitting at:
- -4.47 for the present operating margin
- -1.63 for the gross margin
The net margin for Lucid Group Inc stands at -3.9. The total capital return value is set at -0.41. Equity return is now at value -51.52, with -29.58 for asset returns.
Based on Lucid Group Inc (LCID), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -0.96. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is -977.05.
Currently, EBITDA for the company is -3.1 billion with net debt to EBITDA at -0.37. When we switch over and look at the enterprise to sales, we see a ratio of 13.16. The receivables turnover for the company is 5.89for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.96.
Conclusion
To wrap up, the performance of Lucid Group Inc (LCID) has been bad in recent times. The stock has received a bearish of “sell” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
